Concert recording 2019-10-31

[Track 1]. Traveling somewhere / Alex Wiegel -- [Track 2]. Cold hands / Jacob Albritton -- [Track 3]. Deeper in the dark / Ashlee Steffen -- [Track 4]. Mary / Hunter Anderson -- [Track 5]. My youth / Ashlee Steffen -- [Track 6]. Steps / Bryce Holcomb -- [Track 7]. Fail / Jacob Albritton -- [Track 8]. Pressure / Ashlee Steffen

Concert recording 2017-12-03b

[Track 1]. Boogie wonderland / Earth Wind and Fire -- [Track 2]. Think / Aretha Franklin -- [Track 3]. Please please please / James Brown -- [Track 4]. Your precious love / Tammi Terrell -- [Track 5]. September / Earth Wind and Fire -- [Track 6]. Window seat / Erykah Badu -- [Track 7]. Going down / Norman Whitfield -- [Track 8]. Uptown funk / Mark Ronson, Bruno Mars, Philip Lawrence, Jeff Bhasker, Devon Gallaspy

Concert recording 2018-04-19b

[Track 1]. Sonatina meridional / Manuel Ponce -- [Track 2]. Etude no. 6 / Hector Villa-Lobos -- [Track 3]. Milonga / Jorge Cardoso -- [Track 4]. Straight no chaser / T. Monk -- [Track 5]. A child is born / T. Monk -- [Track 6]. Autumn leaves / J. Kosma -- [Track 7]. Body and soul / J. Green -- [Track 8]. All the things you are / J. Kern -- [Track 9]. 4 on 6 / Wes Montgomery -- [Track 10]. Bright size life / P. Metheny -- [Track 11]. Dueling banjos / Arthur Smith -- [Track 12]. Elenor Rigby / Lennon and McCartney -- [Track 13]. Alone / Bryce Holcomb -- [Track 14]. All around me / Flyleaf -- Vital transformation / Mahavisunu Orchestra

Concert recording 2018-04-14

[Track 1]. Lonely avenue / Ray Charles -- [Track 2]. Boogie wonderland / Earth Wind and Fire -- [Track 3]. Think / Aretha Franklin -- [Track 4]. Please please please / James Brown -- [Track 5]. Your precious love / Tammi Terrell -- [Track 6]. September / Earth Wind and Fire -- [Track 7]. Baby brown eyes / Alisha Jones -- [Track 8]. Window seat / Erykah Badu -- [Track 9]. Smooth criminal / Michael Jackson -- [Track 10]. Going down / Norma Whitfield -- [Track 11]. Uptown funk / Mark Ronson Bruno Mars Philip Lawrence Jeff Bhasker Devon Gallaspy Nicholas Williams -- [Track 12]. Curley green hair / Jacob Skinner -- [Track 13]. You think of her / Shelby Sprott -- [Track 14]. Coffee song / Jordan Strickland Walter Ferguson -- [Track 15]. Leave a trace / Churches -- [Track 16]. Real one / Alisha Jones -- [Track 17]. Reality / Jordan Strickland -- [Track 18]. Still into you / Paramore -- [Track 19]. Alive / Carlie Spiers

Concert recording 2017-12-05a

[Track 1]. Lou Brouwer medley / Brouwer -- [Track 2]. One summer\u27s day / Daniel Asbun -- [Track 3]. What a friend we have in Jesus / Brad Paisley -- [Track 4]. Unity village / Pat Metheny -- [Track 5] Truth? / Asher Perkins -- [Track 6]. Invention no. 13 / J.S. Bach -- [Track 7]. Black Orpheus / Stan Getz arranged Luiz Bonfa -- [Track 8]. Five Hawaiian minutes / Shiro Mori -- [Track 9]. Birks works / Dizzy Gillespie -- [Track 10]. Perhaps / Charlie Parker -- [Track 11]. The river / King Gizzard and the Lizard Wizard -- [Track 12]. Minor swing / Django Reinhardt and Stephan Grappelli -- [Track 13]. Why break mine / Legally blind -- [Track 14]. Monochrome / Carlie Spiers -- [Track 15]. Stuck in voodoo / Dawson Scantling -- [Track 16]. I\u27m saved / Shelby Sprott -- [Track 17]. Newborn / Muse -- [Track 18]. Blueberry brain / Elephantom

Association of Trauma Molecular Endotypes With Differential Response to Transfusion Resuscitation Strategies

IMPORTANCE: It is not clear which severely injured patients with hemorrhagic shock may benefit most from a 1:1:1 vs 1:1:2 (plasma:platelets:red blood cells) resuscitation strategy. Identification of trauma molecular endotypes may reveal subgroups of patients with differential treatment response to various resuscitation strategies. OBJECTIVE: To derive trauma endotypes (TEs) from molecular data and determine whether these endotypes are associated with mortality and differential treatment response to 1:1:1 vs 1:1:2 resuscitation strategies. DESIGN, SETTING, AND PARTICIPANTS: This was a secondary analysis of the Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) randomized clinical trial. The study cohort included individuals with severe injury from 12 North American trauma centers. The cohort was taken from the participants in the PROPPR trial who had complete plasma biomarker data available. Study data were analyzed on August 2, 2021, to October 25, 2022. EXPOSURES: TEs identified by K-means clustering of plasma biomarkers collected at hospital arrival. MAIN OUTCOMES AND MEASURES: An association between TEs and 30-day mortality was tested using multivariable relative risk (RR) regression adjusting for age, sex, trauma center, mechanism of injury, and injury severity score (ISS). Differential treatment response to transfusion strategy was assessed using an RR regression model for 30-day mortality by incorporating an interaction term for the product of endotype and treatment group adjusting for age, sex, trauma center, mechanism of injury, and ISS. RESULTS: A total of 478 participants (median [IQR] age, 34.5 [25-51] years; 384 male [80%]) of the 680 participants in the PROPPR trial were included in this study analysis. A 2-class model that had optimal performance in K-means clustering was found. TE-1 (n = 270) was characterized by higher plasma concentrations of inflammatory biomarkers (eg, interleukin 8 and tumor necrosis factor α) and significantly higher 30-day mortality compared with TE-2 (n = 208). There was a significant interaction between treatment arm and TE for 30-day mortality. Mortality in TE-1 was 28.6% with 1:1:2 treatment vs 32.6% with 1:1:1 treatment, whereas mortality in TE-2 was 24.5% with 1:1:2 treatment vs 7.3% with 1:1:1 treatment (P for interaction = .001). CONCLUSIONS AND RELEVANCE: Results of this secondary analysis suggest that endotypes derived from plasma biomarkers in trauma patients at hospital arrival were associated with a differential response to 1:1:1 vs 1:1:2 resuscitation strategies in trauma patients with severe injury. These findings support the concept of molecular heterogeneity in critically ill trauma populations and have implications for tailoring therapy for patients at high risk for adverse outcomes

Search for gravitational-lensing signatures in the full third observing run of the LIGO-Virgo network

Gravitational lensing by massive objects along the line of sight to the source causes distortions of gravitational wave-signals; such distortions may reveal information about fundamental physics, cosmology and astrophysics. In this work, we have extended the search for lensing signatures to all binary black hole events from the third observing run of the LIGO--Virgo network. We search for repeated signals from strong lensing by 1) performing targeted searches for subthreshold signals, 2) calculating the degree of overlap amongst the intrinsic parameters and sky location of pairs of signals, 3) comparing the similarities of the spectrograms amongst pairs of signals, and 4) performing dual-signal Bayesian analysis that takes into account selection effects and astrophysical knowledge. We also search for distortions to the gravitational waveform caused by 1) frequency-independent phase shifts in strongly lensed images, and 2) frequency-dependent modulation of the amplitude and phase due to point masses. None of these searches yields significant evidence for lensing. Finally, we use the non-detection of gravitational-wave lensing to constrain the lensing rate based on the latest merger-rate estimates and the fraction of dark matter composed of compact objects

Risk Factors for the Development of Acute Respiratory Distress Syndrome Following Hemorrhage

BackgroundThe Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) study evaluated the effects of plasma and platelets on hemostasis and mortality after hemorrhage. The pulmonary consequences of resuscitation strategies that mimic whole blood, remain unknown.MethodsA secondary analysis of the PROPPR study was performed. Injured patients predicted to receive a massive transfusion were randomized to 1:1:1 versus 1:1:2 plasma-platelet-red blood cell ratios at 12 Level I North American trauma centers. Patients with survival >24 h, an intensive care unit (ICU) stay, and a recorded PaO2/FiO2 (P/F) ratio were included. Acute respiratory distress syndrome (ARDS) was defined as a P/F ratio < 200, with bilateral pulmonary infiltrates, and adjudicated by investigators.ResultsFour hundred fifty-four patients were reviewed (230 received 1:1:1, 224 1:1:2). Age, sex, injury mechanism, and regional abbreviated injury scale (AIS) scores did not differ between cohorts. Tidal volume, positive end-expiratory pressure, and lowest P/F ratio did not differ. No significant differences in ARDS rates (14.8% vs. 18.4%), ventilator-free (24 vs. 24) or ICU-free days (17.5 vs. 18), hospital length of stay (22 days vs. 18 days), or 30-day mortality were found (28% vs. 28%). ARDS was associated with blunt injury (OR 3.61 [1.53-8.81] P < 0.01) and increasing chest AIS (OR 1.40 [1.15-1.71] P < 0.01). Each 500 mL of crystalloid infused during hours 0 to 6 was associated with a 9% increase in the rate of ARDS (OR 1.09 [1.04-1.14] P < 0.01). Blood given at 0 to 6 or 7 to 24 h were not risk factors for lung injury.ConclusionAcute crystalloid exposure, but not blood products, is a potentially modifiable risk factor for the prevention of ARDS following hemorrhage

Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma: The PROPPR Randomized Clinical Trial

ImportanceSeverely injured patients experiencing hemorrhagic shock often require massive transfusion. Earlier transfusion with higher blood product ratios (plasma, platelets, and red blood cells), defined as damage control resuscitation, has been associated with improved outcomes; however, there have been no large multicenter clinical trials.ObjectiveTo determine the effectiveness and safety of transfusing patients with severe trauma and major bleeding using plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1:1:2 ratio.Design, setting, and participantsPragmatic, phase 3, multisite, randomized clinical trial of 680 severely injured patients who arrived at 1 of 12 level I trauma centers in North America directly from the scene and were predicted to require massive transfusion between August 2012 and December 2013.InterventionsBlood product ratios of 1:1:1 (338 patients) vs 1:1:2 (342 patients) during active resuscitation in addition to all local standard-of-care interventions (uncontrolled).Main outcomes and measuresPrimary outcomes were 24-hour and 30-day all-cause mortality. Prespecified ancillary outcomes included time to hemostasis, blood product volumes transfused, complications, incidence of surgical procedures, and functional status.ResultsNo significant differences were detected in mortality at 24 hours (12.7% in 1:1:1 group vs 17.0% in 1:1:2 group; difference, -4.2% [95% CI, -9.6% to 1.1%]; P = .12) or at 30 days (22.4% vs 26.1%, respectively; difference, -3.7% [95% CI, -10.2% to 2.7%]; P = .26). Exsanguination, which was the predominant cause of death within the first 24 hours, was significantly decreased in the 1:1:1 group (9.2% vs 14.6% in 1:1:2 group; difference, -5.4% [95% CI, -10.4% to -0.5%]; P = .03). More patients in the 1:1:1 group achieved hemostasis than in the 1:1:2 group (86% vs 78%, respectively; P = .006). Despite the 1:1:1 group receiving more plasma (median of 7 U vs 5 U, P < .001) and platelets (12 U vs 6 U, P < .001) and similar amounts of red blood cells (9 U) over the first 24 hours, no differences between the 2 groups were found for the 23 prespecified complications, including acute respiratory distress syndrome, multiple organ failure, venous thromboembolism, sepsis, and transfusion-related complications.Conclusions and relevanceAmong patients with severe trauma and major bleeding, early administration of plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1:1:2 ratio did not result in significant differences in mortality at 24 hours or at 30 days. However, more patients in the 1:1:1 group achieved hemostasis and fewer experienced death due to exsanguination by 24 hours. Even though there was an increased use of plasma and platelets transfused in the 1:1:1 group, no other safety differences were identified between the 2 groups.Trial registrationclinicaltrials.gov Identifier: NCT01545232